Cyclophosphamide Treatment Options

A collection of 2172 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.

Home

All Treatments

Cyclophosphamide

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

NCT01731886

Completed

The study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in patients with untreated multiple myeloma. This comparison will include how the subjects respond to each study treatment combination, and what side effects are caused by each combination.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/21/2020

Locations: Columbia University, New York, New York

Conditions: Multiple Myeloma

Learn More ›

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

NCT00005803

Completed

This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment. Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect).

Gender:

ALL

Ages:

75 years and below

Trial Updated:

01/17/2020

Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah +4 locations

Conditions: Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia

Learn More ›

Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients

NCT00038142

Terminated

Objectives: 1. To determine if dose intensive Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) with or without ImmTherTM can improve the 2-year disease-free survival seen with standard VAC therapy. 2. To evaluate the feasibility and describe the toxicity associated with VACdxr. 3. To evaluate the feasibility and describe the toxicity of administering ImmTherTM on a weekly basis for 50- 52 weeks. 4. To determine which therapy (VACdxr+ or VACdxr-) is worthy of further evaluatio... Read More

Gender:

ALL

Ages:

Between 3 years and 60 years

Trial Updated:

01/17/2020

Locations: University of Texas MD Anderson Cancer Center, Houston, Texas

Conditions: Ewing's Sarcoma

Learn More ›

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

NCT00453388

Completed

This phase II trial studies how well total-body irradiation (TBI) works when given together with fludarabine phosphate and cyclophosphamide followed by donor bone marrow transplant, mycophenolate mofetil, and cyclosporine in treating patients with Fanconi anemia (FA). Giving low doses of chemotherapy, such as fludarabine phosphate and cyclophosphamide, and TBI before or after a donor bone marrow transplant helps stop the growth of abnormal cells. It may also stop the patient's immune system from... Read More

Gender:

ALL

Ages:

All

Trial Updated:

01/17/2020

Locations: Children's Hospital and Research Center at Oakland, Oakland, California +4 locations

Conditions: Acute Myeloid Leukemia in Remission, de Novo Myelodysplastic Syndrome, Fanconi Anemia, Previously Treated Myelodysplastic Syndrome

Learn More ›

Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation

NCT00057005

Completed

Participants in this study have a hematologic malignancy which is a disorder in the bone marrow that affects the body's ability to create blood. Participants might benefit from receiving an allogeneic stem cell transplant (meaning the cells come from a donor). The participants donor is a family member. Stem cells are cells in the bone marrow and blood that can form a whole new blood system.

Gender:

ALL

Ages:

45 years and below

Trial Updated:

01/15/2020

Locations: Texas Children's Hospital, Houston, Texas +1 locations

Conditions: LEUKEMIA

Learn More ›

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

NCT00040469

Terminated

The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.

Gender:

ALL

Ages:

Between 1 day and 64 years

Trial Updated:

01/15/2020

Locations: Texas Children's Hospital, Houston, Texas +1 locations

Conditions: Sickle Cell Anemia, Hemoglobinopathy, Thalassemia

Learn More ›

High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis

NCT00040482

Completed

Multiple Sclerosis is a disease that may be caused by the immune system reacting against the nervous system. It is possible, that by changing the immune system we can modify the progression of this disease. In this study, we will try to learn whether treatment with a bone marrow transplant (BMT) can help patients with multiple sclerosis. We will also try to learn what the side effects are of this treatment in patients with multiple sclerosis.

Gender:

ALL

Ages:

Between 18 years and 60 years

Trial Updated:

01/15/2020

Locations: The Methodist Hospital, Houston, Texas

Conditions: Multiple Sclerosis

Learn More ›

Stem Cell Transplant to Treat Patients With Systemic Sclerosis

NCT00058578

Completed

Systemic Sclerosis is a disease that may be caused by the immune system reacting against skin and certain organs. It is possible, that by changing the immune system we can modify the progression of this disease. Stem cells are created in the bone marrow. They mature into different types of blood cells that are needed including red blood cells, white blood cells, and platelets. In this study, we will stimulate the bone marrow to make extra stem cells. Next we will collect the stem cells, select... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

01/15/2020

Locations: The Methodist Hospital, Houston, Texas

Conditions: Systemic Sclerosis

Learn More ›

T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts

NCT00368355

Completed

Subjects are being asked to participate in this study because treatment of their disease requires them to receive a stem cell transplant. Stem cells or "mother" cells are the source of normal blood cells and lead to recovery of blood counts after bone marrow transplantation (BMT). Unfortunately, there is not a perfectly matched stem cell donor (like a sister or brother) and the subject's disease is considered rapidly progressive and does not permit enough time to identify another donor (like someone from a registry list that is not their relative). We have, however, identified a close relative of the subject's whose stem cells are not a perfect match, but can be used. However, with this type of donor, there is typically an increased risk of developing graft-versus-host disease (GVHD), a high rate of transplant failure, and a longer delay in the recovery of the immune system. GVHD is a serious and sometimes fatal side effect of stem cell transplant. GVHD occurs when the new donor cells (graft) recognizes that the body tissues of the patient (host) are different from those of the donor. When this happens, cells in the graft may attack the host organs, primarily the skin, liver, and intestines. The number of occurrences and harshness of severe GVHD depends on several factors, including the degree of genetic differences between the donor and recipient, the intensity of the pre-treatment conditioning regimen, the quantity of transplanted cells, and the recipient's age. In recipients of mismatched family member or matched unrelated donor stem cell transplants, there is a greater risk of GVHD so that 70-90% of recipients of unchanged marrow will develop severe GVHD which could include symptoms such as marked diarrhea, liver failure, or even death. In an effort to lower the occurrences and severity of graft-versus-host disease in patients and to lower the rate of transplant failure, we would like to specially treat the donor's blood cells to remove cells that are most likely to attack the patient's tissues. This will occur in combination with intense conditioning treatment that the patient will receive before the transplant. Read Less

Gender:

ALL

Ages:

55 years and below

Trial Updated:

01/15/2020

Locations: Houston Methodist Hospital, Houston, Texas +1 locations

Conditions: Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Hemophagocytic Lymphohistiocytosis (HLH), Familial Hemophagocytic Lymphohistiocytosis (FLH), Viral-associated Hemophagocytic Syndrome (VAHS), X-linked Lymphoproliferative Disease (XLP)

Learn More ›

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

NCT00789776

Completed

This phase I/II trial studies the side effects and best dose of donor natural killer (NK) cell therapy and to see how well it works when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, donor bone marrow transplant, mycophenolate mofetil, and tacrolimus in treating patients with hematologic cancer. Giving chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total-body irradiation before a donor bone marrow transplant helps stop the growth of c... Read More

Gender:

ALL

Ages:

All

Trial Updated:

01/15/2020

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington +2 locations

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Previously Treated Myelodysplastic Syndrome, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia

Learn More ›

High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma

NCT00354744

Completed

RATIONALE: Drugs used in chemotherapy, such as vincristine, irinotecan, ifosfamide, etoposide, doxorubicin, cyclophosphamide, and dactinomycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving high-dose combination chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase III trial is studying how well giving high-dose co... Read More

Gender:

ALL

Ages:

49 years and below

Trial Updated:

01/15/2020

Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +165 locations

Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama

Phoenix Children's Hospital, Phoenix, Arizona

Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas

Southern California Permanente Medical Group, Downey, California

Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California

Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California

Childrens Hospital Los Angeles, Los Angeles, California

Children's Hospital Central California, Madera, California

Children's Hospital and Research Center Oakland, Oakland, California

Children's Hospital of Orange County, Orange, California

Sutter Cancer Center, Sacramento, California

University of California Davis Cancer Center, Sacramento, California

Kaiser Permanente Medical Center - Oakland, Sacramento, California

Rady Children's Hospital - San Diego, San Diego, California

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Stanford Cancer Center, Stanford, California

Children's Hospital Center for Cancer and Blood Disorders, Aurora, Colorado

Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut

Alfred I. duPont Hospital for Children, Wilmington, Delaware

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia

Children's National Medical Center, Washington, District of Columbia

Walter Reed Army Medical Center, Washington, District of Columbia

Broward General Medical Center Cancer Center, Fort Lauderdale, Florida

Lee Cancer Care of Lee Memorial Health System, Fort Myers, Florida

University of Florida Shands Cancer Center, Gainesville, Florida

Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida

Nemours Children's Clinic, Jacksonville, Florida

Miami Children's Hospital, Miami, Florida

Baptist-South Miami Regional Cancer Program, Miami, Florida

Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida

M.D. Anderson Cancer Center at Orlando, Orlando, Florida

Nemours Children's Clinic - Orlando, Orlando, Florida

Sacred Heart Cancer Center at Sacred Heart Hospital, Pensacola, Florida

All Children's Hospital, Saint Petersburg, Florida

St. Joseph's Cancer Institute at St. Joseph's Hospital, Tampa, Florida

Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida

Winship Cancer Institute of Emory University, Atlanta, Georgia

MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia

Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia

Cancer Research Center of Hawaii, Honolulu, Hawaii

University of Illinois Cancer Center, Chicago, Illinois

Children's Memorial Hospital - Chicago, Chicago, Illinois

University of Chicago Cancer Research Center, Chicago, Illinois

Advocate Christ Medical Center, Oak Lawn, Illinois

Advocate Lutheran General Cancer Care Center, Park Ridge, Illinois

Saint Jude Midwest Affiliate, Peoria, Illinois

Simmons Cooper Cancer Institute, Springfield, Illinois

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

St. Vincent Indianapolis Hospital, Indianapolis, Indiana

Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas

Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky

Kosair Children's Hospital, Louisville, Kentucky

Tulane Cancer Center Office of Clinical Research, Alexandria, Louisiana

Children's Hospital of New Orleans, New Orleans, Louisiana

Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

Floating Hospital for Children at Tufts - New England Medical Center, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts

C.S. Mott Children's Hospital at University of Michigan Medical Center, Ann Arbor, Michigan

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Hurley Medical Center, Flint, Michigan

Butterworth Hospital at Spectrum Health, Grand Rapids, Michigan

CCOP - Kalamazoo, Kalamazoo, Michigan

Breslin Cancer Center at Ingham Regional Medical Center, Lansing, Michigan

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota

University of Minnesota Cancer Center, Minneapolis, Minnesota

Mayo Clinic Cancer Center, Rochester, Minnesota

University of Mississippi Cancer Clinic, Jackson, Mississippi

Children's Mercy Hospital, Kansas City, Missouri

Siteman Cancer Center at Barnes-Jewish St. Peters Hospital - Saint Louis, Saint Louis, Missouri

Children's Hospital, Omaha, Nebraska

UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska

Sunrise Hospital and Medical Center, Las Vegas, Nevada

Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Hackensack University Medical Center Cancer Center, Hackensack, New Jersey

Overlook Hospital, Morristown, New Jersey

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey

Newark Beth Israel Medical Center, Newark, New Jersey

St. Joseph's Hospital and Medical Center, Paterson, New Jersey

University of New Mexico Cancer Center, Albuquerque, New Mexico

Albany Medical Center Hospital, Albany, New York

Roswell Park Cancer Institute, Buffalo, New York

Schneider Children's Hospital, New Hyde Park, New York

NYU Cancer Institute at New York University Medical Center, New York, New York

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York

Stony Brook University Cancer Center, Stony Brook, New York

SUNY Upstate Medical University Hospital, Syracuse, New York

New York Medical College, Valhalla, New York

Mission Hospitals - Memorial Campus, Asheville, North Carolina

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina

Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina

Duke Comprehensive Cancer Center, Durham, North Carolina

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina

Akron Children's Hospital, Akron, Ohio

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Rainbow Babies and Children's Hospital, Cleveland, Ohio

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Nationwide Children's Hospital, Columbus, Ohio

Children's Medical Center - Dayton, Dayton, Ohio

Toledo Hospital, Toledo, Ohio

Medical University of Ohio Cancer Center, Toledo, Ohio

Oklahoma University Cancer Institute, Oklahoma City, Oklahoma

Oregon Health and Science University Cancer Institute, Portland, Oregon

Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania

Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania

Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina

Palmetto Health South Carolina Cancer Center, Columbia, South Carolina

Greenville Hospital Cancer Center, Greenville, South Carolina

Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota

T.C. Thompson Children's Hospital, Chattanooga, Tennessee

East Tennessee Children's Hospital, Knoxville, Tennessee

St. Jude Children's Research Hospital, Memphis, Tennessee

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Texas Tech University Health Sciences Center School of Medicine - Amarillo, Amarillo, Texas

Dell Children's Medical Center of Central Texas, Austin, Texas

Driscoll Children's Hospital, Corpus Christi, Texas

Medical City Dallas Hospital, Dallas, Texas

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas

Cook Children's Medical Center - Fort Worth, Fort Worth, Texas

Baylor University Medical Center - Houston, Houston, Texas

M. D. Anderson Cancer Center at University of Texas, Houston, Texas

Covenant Children's Hospital, Lubbock, Texas

University of Texas Health Science Center at San Antonio, San Antonio, Texas

Methodist Children's Hospital of South Texas, San Antonio, Texas

CCOP - Scott and White Hospital, Temple, Texas

Primary Children's Medical Center, Salt Lake City, Utah

Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont

Inova Fairfax Hospital, Falls Church, Virginia

Children's Hospital of The King's Daughters, Norfolk, Virginia

Carilion Medical Center for Children at Roanoke Community Hospital, Roanoke, Virginia

Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington

Providence Cancer Center at Sacred Heart Medical Center, Spokane, Washington

Mary Bridge Children's Hospital and Health Center - Tacoma, Tacoma, Washington

West Virginia University Health Sciences Center - Charleston, Charleston, West Virginia

Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin

Midwest Children's Cancer Center, Milwaukee, Wisconsin

John Hunter Hospital, Newcastle, New South Wales

Westmead Institute for Cancer Research at Westmead Hospital, Westmead, New South Wales

Royal Children's Hospital, Herston, Brisbane, Queensland

Women's and Children's Hospital, North Adelaide, South Australia

Royal Children's Hospital, Parkville, Victoria

Princess Margaret Hospital for Children, Perth, Western Australia

Alberta Children's Hospital, Calgary, Alberta

University of Alberta Hospital, Edmonton, Alberta

Children's & Women's Hospital of British Columbia, Vancouver, British Columbia

CancerCare Manitoba, Winnipeg, Manitoba

Janeway Children's Health and Rehabilitation Centre, St. John's, Newfoundland and Labrador

IWK Health Centre, Halifax, Nova Scotia

McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario

Children's Hospital of Western Ontario, London, Ontario

Children's Hospital of Eastern Ontario, Ottawa, Ontario

Hospital for Sick Children, Toronto, Ontario

Montreal Children's Hospital at McGill University Health Center, Montreal, Quebec

Hopital Sainte Justine, Montreal, Quebec

Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon, Saskatchewan

Centre Hospitalier Universitaire de Quebec, Quebec, Not set

San Jorge Children's Hospital, Santurce, Not set

Swiss Pediatric Oncology Group Bern, Bern, Not set

Conditions: Sarcoma

Learn More ›

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

NCT00490529

Completed

Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Participants will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. This vaccination may prolong the time which patients will stay in remission from their disease.

Gender:

ALL

Ages:

Between 21 years and 70 years

Trial Updated:

01/08/2020

Locations: Stanford University Medical Center, Stanford, California

Conditions: Lymphoma, Mantle-Cell

Learn More ›